{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-039981","form_type":"8-K","ticker":"IMDX","cik":"0001642380","company_name":"Insight Molecular Diagnostics Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.915728+00:00","generated_at":"2026-06-08T06:50:32.862054+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Oncocyte Q3 rev $0.4M, op loss $6.5M; VitaGraft Kidney gets CMS coverage","bullets":["Revenue $0.4M; net operating loss $6.5M vs $1.7M in Q3 2022 (which included $6.1M fair value benefit).","Cash burn reduced to $3.6M; cash, equivalents, and marketable securities $14.2M as of Sep 30, 2023.","VitaGraft Kidney received positive CMS coverage decision; commercial revenue expected in 1H 2024.","R&D expense $2.2M (+48% YoY) driven by assay development; SG&A $2.5M (-56% YoY) due to lower stock compensation.","VitaGraft Liver under review for CMS coverage at MolDX."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-039981","json":"https://secwatch.observer/filing/0001493152-23-039981.json","markdown":"https://secwatch.observer/filing/0001493152-23-039981.md","text":"https://secwatch.observer/filing/0001493152-23-039981.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1642380/000149315223039981/0001493152-23-039981-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1642380/000149315223039981/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:50:32.862054+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5fce5199b7c848ffe665cf6e35b146423eedf842","claim":"Insight Molecular Diagnostics Inc. reported third quarter ended September 30, 2023 results: revenue $0.4 million, net income $6.5 million net consolidated operating loss.","evidence_excerpt":"for growth in 2024 and the years beyond,” concluded Mr. Riggs. Third Quarter 2023 Financial Results Consolidated revenue for the third quarter of 2023 was approximately $0.4 million primarily due to increased revenue from Pharma Services. Cost of revenue was approximately $0.2 million. Net consolidated operating loss for the three months ended September 30,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315223039981/0001493152-23-039981-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$0.4 million"},{"label":"Net income","value":"$6.5 million net consolidated operating loss"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}